Indiana’s long-established bioscience sector has formally adopted a new umbrella identity. BioHeartland is a move designed to unify the state’s life sciences ecosystem and strengthen its positioning as a highly competitive national and global market for talent, investments and innovation.
The rebrand was introduced recently in an announcement from the collaborative effort led by the CEOs of Indiana Corporate Partnership (CICP) and its branded initiatives, BioCrossroads and AgriNovus Indiana, in partnership with the Central Indiana Regional Development Authority. The goal is to better package Indiana’s decades-long strengths in pharmaceuticals, medical devices, agricultural bioscience and advanced manufacturing under a single, recognizable banner. Ultimately, BioHeartland seeks to ensure that Indiana’s impressive life sciences story is heard and received on a global scale.
“Whether your day-to-day work is more focused on human health, animal health or plant health, you are contributing to a single, interconnected bioscience engine that is driving our economy forward and our reputation as well,” said Christy Wright, President and CEO of AgriNovus Indiana. “And that is the opportunity in front of us – to talk about ourselves in a way that reflects the full picture and resonates far beyond our state’s borders.”
BioHeartland will function as a strategic identity for the state’s bioscience cluster, which has already developed into one of the strongest life sciences economies in the country.
“When you look at our bioscience strengths across human health, animal health and plant sciences, it’s not a side story in our economy. It’s actually the main engine of our economic growth,” said Melina Kennedy, President and CEO of CICP.
The state’s biosciences sector has been built on a strong foundation of large-scale manufacturing, research institutions and a network of companies ranging from biotech startups to global pharmaceutical producers. Most recently, the state of Indiana committed over $1 billion to the life sciences sector in the central area of the state. This adds to the billions already invested and the multibillion-dollar impact the industry has provided.
“That confidence is grounded in both capabilities and impact. From a capability perspective, we offer a unique integrated value chain of research and development, manufacturing and logistics,” said Vince Wong, President and CEO of BioCrossroads. “Put simply, we invent it, we make it, and we move it.”
Indiana has long benefitted from structural advantages in biosciences that include a central geographic location, lower operating costs than coastal hubs, and a strong logistics infrastructure that supports distribution and advanced manufacturing. The sector is also supported by major research universities and agencies dedicated to reinforcing the workforce pipeline.
As a result, Wong told attendees at the branding announcement that Indiana’s life sciences path projection is three times that of the national average. As BioHeartland connects those assets into a coordinated bioscience ecosystem, it positions the local industry to be even more competitive, both nationally and internationally.
As global demand for healthcare innovation, biotechnology and advanced therapeutics continues to rise, the ability of regions to clearly communicate their strengths matters even more. BioHeartland represents a strategy effort to take a well-established industry and give it a sharper, more unified identity to help shape its next phase of growth.
